Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
April 23, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 23, 2024 (GLOBE NEWSWIRE) -- Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca,...
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
April 23, 2024 08:00 ET
|
Recludix Pharma, Inc.
Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
Breast Cancer Market To Reach USD 4.3 Billion By 2032, Says DataHorizzon Research
April 23, 2024 05:40 ET
|
DataHorizzon Research
Fort Collins, Colorado, April 23, 2024 (GLOBE NEWSWIRE) -- The growing prevalence of breast cancer drives the need for diagnostics in the forecast period. The prevalence of breast cancer...
Sleep Medications Market to hit USD 38.7 Bn by 2032, says Global Market Insights Inc.
April 23, 2024 04:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware, April 23, 2024 (GLOBE NEWSWIRE) -- Sleep Medications Market Size is projected to reach USD 38.7 billion by the end of 2032. The growing advances in pharmaceutical R&D...
Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire
April 23, 2024 01:00 ET
|
Sanofi - Aventis Groupe
L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire Des données pivots de la première étude de phase III...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
April 23, 2024 01:00 ET
|
Sanofi - Aventis Groupe
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential...
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024 17:54 ET
|
Regeneron Pharmaceuticals, Inc.
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations...
Antacids Market Size Expected to Reach USD 9.64 Bn by 2032
April 22, 2024 11:00 ET
|
Precedence Research
Ottawa, April 22, 2024 (GLOBE NEWSWIRE) -- The global antacids market size was valued at USD 7.20 billion in 2023 and is predicted to surpass around USD 9.29 billion by 2031, a study published by...
Probiotic Ingredients Market Size is expected to reach USD 7.48 billion by 2031, growing at a CAGR of 4.20%: Straits Research
April 22, 2024 11:00 ET
|
Straits Research Private Limited - Reed Intelligence
New York, United States, April 22, 2024 (GLOBE NEWSWIRE) -- Probiotics are microorganisms consumed to enhance the function of the digestive system. These microorganisms, also known as beneficial or...
Loratadine Market to Garner $221.4 Billion, Globally, by 2033 at 3.1% CAGR: The Brainy Insights
April 22, 2024 07:00 ET
|
The Brainy Insights
Newark, April 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 163.2 billion loratadine market will reach USD 221.4 billion by 2033. Loratadine is an antihistamine drug. All...